Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The main purpose is to evaluate the clinical response, safety and survival of the FDA
approved drugs Dabrafenib, Trametinib in combination with Metformin. Investigators
hypothesize that the combination of an FDA approved non toxic dose of oral Metformin with the
B-Raf inhibitor, Dabrafenib and the MEK inhibitor, Trametinib will yield little toxicity and
improve clinical outcomes in terms of objective response rates and survival in metastatic
melanoma patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
James Graham Brown Cancer Center University of Louisville
Collaborators:
James Graham Brown Cancer Center University of Louisville